Selective androgen receptor modulators (SARMs) differentially bind to androgen receptors based on each SARM’s chemical structure. As a result, SARMs lead to anabolic cellular activity while avoiding most of the side effects of currently available steroid drugs. SARMs have already been studied in the management of cancer of the breast and cachexia and still have also been used as performance-enhancing agents. Here, we evaluate and summarize the existing literature on SARMs.
Aim
To give the history, mechanisms, current and potential clinical applications, in addition to risks and advantages of SARMs.
Methods
A literature review was performed in MEDLINE with all the terms selective androgen receptor modulator, hypogonadism, cachexia, cancers of the breast, benign prostatic hyperplasia, libido, and muscle tissue. Both basic research and clinical tests were included.
Main Outcome Measure
To perform overview of peer-reviewed literature.
Results
However, there are still no U.S. Drug and food Agency-approved indications for SARMs, investigators are studying the potential purposes of these compounds. Research has centered on the pharmacokinetics and pharmacodynamics of these agents, demonstrating good availability using a paucity of drug interactions. Early clinical studies have demonstrated potential purposes of SARMs inside the treating cancer-related cachexia, benign prostatic hyperplasia (BPH), hypogonadism, and breast cancers, with good success.
Conclusion
SARMs have a lot of possible clinical applications, with promise to the safe utilization in the treatment of cachexia, BPH, hypogonadism, breast cancer, and prostate type of cancer.
More information about Sarms for sale see this useful web portal.
